S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:ARCT

Arcturus Therapeutics Stock Forecast, Price & News

$63.77
-3.53 (-5.25 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$61.63
Now: $63.77
$69.14
50-Day Range
$42.36
MA: $81.99
$123.66
52-Week Range
$8.51
Now: $63.77
$129.71
Volume1.86 million shs
Average Volume2.78 million shs
Market Capitalization$1.56 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.01
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics logo

MarketRank

Overall MarketRank

1.43 out of 5 stars

Medical Sector

507th out of 1,926 stocks

Pharmaceutical Preparations Industry

251st out of 773 stocks

Analyst Opinion: 2.2Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ARCT
CUSIPN/A
Phone858-900-2660
Employees88

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20.79 million
Book Value$1.70 per share

Profitability

Net Income$-25,990,000.00
Net Margins-506.70%

Miscellaneous

Market Cap$1.56 billion
Next Earnings Date3/10/2021 (Estimated)
OptionableOptionable
$63.77
-3.53 (-5.25 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ARCT News and Ratings via Email

Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Arcturus Therapeutics (NASDAQ:ARCT) Frequently Asked Questions

How has Arcturus Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ARCT shares have increased by 387.2% and is now trading at $63.77.
View which stocks have been most impacted by COVID-19
.

Is Arcturus Therapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Arcturus Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares.
View analyst ratings for Arcturus Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Arcturus Therapeutics?

Wall Street analysts have given Arcturus Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arcturus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Arcturus Therapeutics' CEO?

1,448 employees have rated Arcturus Therapeutics CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Arcturus Therapeutics' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Arcturus Therapeutics' next earnings date?

Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Arcturus Therapeutics
.

How were Arcturus Therapeutics' earnings last quarter?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) released its quarterly earnings results on Saturday, November, 14th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.43. The biotechnology company had revenue of $2.33 million for the quarter, compared to analyst estimates of $3.17 million. Arcturus Therapeutics had a negative net margin of 506.70% and a negative return on equity of 52.32%.
View Arcturus Therapeutics' earnings history
.

What price target have analysts set for ARCT?

12 Wall Street analysts have issued twelve-month price targets for Arcturus Therapeutics' shares. Their forecasts range from $19.00 to $133.00. On average, they anticipate Arcturus Therapeutics' share price to reach $69.21 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price.
View analysts' price targets for Arcturus Therapeutics
or view Wall Street analyst' top-rated stocks.

Are investors shorting Arcturus Therapeutics?

Arcturus Therapeutics saw a drop in short interest in December. As of December 31st, there was short interest totaling 3,700,000 shares, a drop of 19.4% from the December 15th total of 4,590,000 shares. Based on an average daily volume of 987,000 shares, the days-to-cover ratio is currently 3.7 days.
View Arcturus Therapeutics' Short Interest
.

Who are some of Arcturus Therapeutics' key competitors?

What other stocks do shareholders of Arcturus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and (SNY).

Who are Arcturus Therapeutics' key executives?

Arcturus Therapeutics' management team includes the following people:
  • Mr. Joseph E. Payne M.Sc., Founder, Pres, CEO & Director (Age 48, Pay $693k)
  • Dr. Padmanabh Chivukula, Founder, Chief Scientific Officer, COO & Sec. (Age 41, Pay $503.2k)
  • Mr. Andrew H. Sassine, CFO & Director (Age 56, Pay $525k)
  • Mr. J.P. Headley, Associate Director of Accounting & Operations
  • Ms. Neda Safarzadeh, Director and Head of Investor Relations/PR & Marketing
  • Mr. Lance Kurata, Chief Legal Officer
  • Ms. Jessica Mendez, Associate Director of HR
  • Mr. Kevin T. Skol, Sr. VP of Bus. Devel. & Alliance Management
  • Dr. Steven George Hughes M.B.A., M.D., Chief Devel. Officer (Age 53)
  • Mr. Keith C. Kummerfeld CPA, VP of Fin. & Corp. Controller

What is Arcturus Therapeutics' stock symbol?

Arcturus Therapeutics trades on the NASDAQ under the ticker symbol "ARCT."

Who are Arcturus Therapeutics' major shareholders?

Arcturus Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Dfpg Investments LLC (0.36%), Exchange Traded Concepts LLC (0.03%) and Pacer Advisors Inc. (0.01%). Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc.
View institutional ownership trends for Arcturus Therapeutics
.

Which major investors are selling Arcturus Therapeutics stock?

ARCT stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc.
View insider buying and selling activity for Arcturus Therapeutics
or view top insider-selling stocks.

Which major investors are buying Arcturus Therapeutics stock?

ARCT stock was bought by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, and Pacer Advisors Inc.. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell.
View insider buying and selling activity for Arcturus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Arcturus Therapeutics?

Shares of ARCT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Arcturus Therapeutics' stock price today?

One share of ARCT stock can currently be purchased for approximately $63.77.

How big of a company is Arcturus Therapeutics?

Arcturus Therapeutics has a market capitalization of $1.56 billion and generates $20.79 million in revenue each year. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. Arcturus Therapeutics employs 88 workers across the globe.

What is Arcturus Therapeutics' official website?

The official website for Arcturus Therapeutics is www.arcturusrx.com.

How can I contact Arcturus Therapeutics?

Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.